search
Back to results

Time Restricted Diet in Obese or Overweight Pre or Postmenopausal Participants

Primary Purpose

Healthy, no Evidence of Disease, Obesity

Status
Terminated
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
behavioral dietary intervention
telephone-based intervention
laboratory biomarker analysis
Sponsored by
Northwestern University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Healthy, no Evidence of Disease

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)FemaleAccepts Healthy Volunteers

Inclusion Criteria:

  • Subjects must have a stable weight (have not gained or lost 25 pounds in the last 6 months)
  • Subjects must have had a normal mammogram within 9 months prior to registration; NOTE: subjects must also have a normal breast exam on the day of the pre-intervention random fine needle aspiration (rFNA)
  • Subjects must have a body mass index (BMI) of 25-40
  • Subjects must fit into ONE of the following menopausal categories:

    • Premenopausal (n = 40) - defined as meeting all the following criteria:

      • Have had at least 8 menstrual cycles in the past 12 months
      • Have had no hormonal contraception in the past 3 months prior to registration
      • Have serum hormone parameters (estradiol [E2], progesterone, follicle stimulating hormone [FSH]) in premenopausal range on the day of rFNA; NOTE: subjects will self-report menopausal status at registration, and confirmation of hormonal parameters will occur after registration as part of pre-intervention procedures; if there is mis-assignment of status, the recruitment of future subjects will be adjusted accordingly
    • Postmenopausal (n = 40) - defined as meeting all of the following criteria:

      • Last menstrual period (LMP) > 1 year previously
      • Have had no hormone use in the past 3 months prior to registration
      • Serum E2, progesterone, FSH in postmenopausal range on the day of rFNA; NOTE: subjects will self-report menopausal status at registration, and confirmation of hormonal parameters will occur after registration as part of pre-intervention procedures; if there is mis-assignment of status, the recruitment of future subjects will be adjusted accordingly
  • Subjects must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
  • Subjects who have been diagnosed with a prior cancer at any site (other than breast cancer) may participate as long as they have been off medical therapy for at least 12 months prior to registration
  • Subjects with prior breast cancer must be off all systemic therapy (including endocrine agents) for at least 2 years prior to registration
  • Subjects must be willing to undergo a random fine needle aspiration (rFNA) at the beginning and end of the intervention period
  • Subjects must be willing and able to abstain from the use of aspirin for at least 2 weeks prior to undergoing each rFNA procedure (pre- and post-intervention)
  • Subjects must have the ability to understand and the willingness to sign a written informed consent prior to registration on study
  • Subjects must have a smart phone (newer generation Android or any Iphone) to be able to track their food intake times
  • Subjects must be willing to restrict food intake to an 8 hour period every day (12 pm to 8 pm)

Exclusion Criteria:

  • Subjects who have received hormonal contraception and/or hormone therapy in the past 3 months are not eligible
  • Subjects who are pregnant and/or lactating are not eligible
  • Subjects who are noted (upon initial online screening) to do 150 minutes or more of moderate level physical activity each week, get less than 8% of their calories from saturated fat, and eat more than 5 fruit and vegetable servings per day will not be eligible
  • Subjects who are part of any structured weight loss programs (e.g. Weight Watchers, etc.) are not eligible
  • Subjects who have undergone bariatric surgery are not eligible
  • Subjects who work night shifts are not eligible
  • Subjects who have diabetes or uncontrolled hypertension are not eligible; NOTE: for the purposes of this study, uncontrolled will be defined as diastolic pressure over 100 mmHg

Sites / Locations

  • Northwestern University

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Behavioral (time restricted diet)

Arm Description

Participants follow a time restricted diet, which restricts daily eating to an 8 hour time window between 12:00-8:00 pm. Participants are allowed to consume non-caloric beverages (water, black tea, black coffee, diet soda, etc.) during the fasting hours and required to record daily food consumption in the smartphone app for 6 months. Participants are also coached by telephone over approximately 10-15 minutes weekly for 1 month and then biweekly for 5 months.

Outcomes

Primary Outcome Measures

Adherence to self-monitoring
Assessed by demonstrating that at least 65% of participants record dietary intake on at least 80% of study intervention days. Adherence will be assessed via a one-sample chi-squared test for proportions.
Attaining the goal of dietary time restriction
Assessed by demonstrating that at least 65% of participants recorded appropriate time restriction on at least 80% of study days.

Secondary Outcome Measures

Changes in steroid hormones (estradiol, progesterone, testosterone) levels
Blood samples will be taken and representative values (mean, standard deviation, median, and range) of hormones and adipokine measurements will be used to calculate changes following intervention, which will then be used for univariate analysis using menopausal status and change in BMI as the main predictors of interest. These analyses are exploratory and descriptive of the systemic endocrine/adipokine environment; they will be related to gene expression changes. Correlations between changes in BMI and changes in biomarker levels will be assessed via the Spearman correlation.
Changes in gonadotropins (FSH) levels
Blood samples will be taken and representative values (mean, standard deviation, median, and range) of hormones and adipokine measurements will be used to calculate changes following intervention, which will then be used for univariate analysis using menopausal status and change in BMI as the main predictors of interest. These analyses are exploratory and descriptive of the systemic endocrine/adipokine environment; they will be related to gene expression changes. Correlations between changes in BMI and changes in biomarker levels will be assessed via the Spearman correlation.
Changes in insulin axis (insulin, insulin-like growth factor 1, IGF binding protein 3, homeostatic model assessment, homocystein) levels
Blood samples will be taken and representative values (mean, standard deviation, median, and range) of hormones and adipokine measurements will be used to calculate changes following intervention, which will then be used for univariate analysis using menopausal status and change in BMI as the main predictors of interest. These analyses are exploratory and descriptive of the systemic endocrine/adipokine environment; they will be related to gene expression changes. Correlations between changes in BMI and changes in biomarker levels will be assessed via the Spearman correlation.
Changes in adipokines (leptin, adiponectin, low molecular weight adiponectin) levels
Blood samples will be taken and representative values (mean, standard deviation, median, and range) of hormones and adipokine measurements will be used to calculate changes following intervention, which will then be used for univariate analysis using menopausal status and change in BMI as the main predictors of interest. These analyses are exploratory and descriptive of the systemic endocrine/adipokine environment; they will be related to gene expression changes. Correlations between changes in BMI and changes in biomarker levels will be assessed via the Spearman correlation.
Changes in inflammatory axis (interleukin-6, tumor necrosis factor alpha) levels
Blood samples will be taken and representative values (mean, standard deviation, median, and range) of hormones and adipokine measurements will be used to calculate changes following intervention, which will then be used for univariate analysis using menopausal status and change in BMI as the main predictors of interest. These analyses are exploratory and descriptive of the systemic endocrine/adipokine environment; they will be related to gene expression changes. Correlations between changes in BMI and changes in biomarker levels will be assessed via the Spearman correlation.
Changes in weight
The pre- and post-intervention measures and within-individual changes in weight be summarized and examined for Normality and outliers; required transformations to achieve Normality will be performed.
Changes in BMI
The pre- and post-intervention measures and within-individual changes in BMI will be summarized and examined for Normality and outliers; required transformations to achieve Normality will be performed. Pre-post comparisons of BMI will be performed using paired Wilcoxon signed-rank tests to evaluate changes over time, designating P < 0.05 as significant.
Changes in breast epithelial gene expression
Gene expression for all 58 genes on the Taqman low density gene expression assays will be summarized to confirm normality and discern outliers. Each gene will then be analyzed using a linear model with the main effect of menopausal status and change in BMI, baseline gene expression and change in expression will be correlated to baseline steroid hormones and adipokines, and their change. If severe departure from normality is observed, these linear models will be applied to ranks of the data.
Changes in parenchymal volume assessed by MRI
The volume of parenchymal enhancement on MRI will be assessed pre and post intervention in women who consent to this optional component.

Full Information

First Posted
June 2, 2014
Last Updated
August 27, 2020
Sponsor
Northwestern University
Collaborators
Avon Foundation Center of Excellence, National Cancer Institute (NCI)
search

1. Study Identification

Unique Protocol Identification Number
NCT02154984
Brief Title
Time Restricted Diet in Obese or Overweight Pre or Postmenopausal Participants
Official Title
A Pilot Study of Time Restricted Diet in Obese/Overweight Pre &Amp; Postmenopausal Women
Study Type
Interventional

2. Study Status

Record Verification Date
August 2020
Overall Recruitment Status
Terminated
Why Stopped
Study closed due to funding before accrual was met
Study Start Date
July 2014 (Actual)
Primary Completion Date
February 23, 2017 (Actual)
Study Completion Date
February 23, 2017 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Northwestern University
Collaborators
Avon Foundation Center of Excellence, National Cancer Institute (NCI)

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The purpose of this study is to study the relationships between obesity, hormones and menopausal status, and breast cancer. The researchers would like to study whether a type of nutritional intervention, called a time-restricted diet or tRD, is easy to maintain using a smartphone application; the researchers also want to study the effect that a tRD has on weight control, hormones, and breast tissue. A tRD is a type of diet that requires people to restrict their daily eating to a specific time frame each day. The researchers think that this might be an effective and manageable way to control weight.
Detailed Description
PRIMARY OBJECTIVES: I. Feasibility of fostering adherence to self-monitoring of dietary intake using a smartphone application (app). II. Feasibility of the goal of following a time-restricted diet. SECONDARY OBJECTIVES: I. Identify potential molecular biomarkers and/or signatures to explore its efficacy for the normalization of metabolism. II. Assess the systemic endocrine effects of a time restricted diet (tRD) intervention in overweight and obese pre and postmenopausal women. III. Assess weight change following a tRD intervention. IV. Evaluate the effects of a tRD intervention, and identify a specific and reproducible genomic signature, in breast samples obtained by random fine needle aspiration in the tRD study population. V. Assess the volume of parenchymal enhancement on magnetic resonance imaging (MRI). OUTLINE: Participants follow a time restricted diet, which restricts daily eating to an 8 hour time window between 12:00-8:00 pm. Participants are allowed to consume non-caloric beverages (water, black tea, black coffee, diet soda, etc.) during the fasting hours and required to record daily food consumption in the smartphone app for 6 months. Participants are also coached by telephone over approximately 10-15 minutes weekly for 1 month and then biweekly for 5 months. After completion, participants are followed up for 3 months.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Healthy, no Evidence of Disease, Obesity

7. Study Design

Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
45 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Behavioral (time restricted diet)
Arm Type
Experimental
Arm Description
Participants follow a time restricted diet, which restricts daily eating to an 8 hour time window between 12:00-8:00 pm. Participants are allowed to consume non-caloric beverages (water, black tea, black coffee, diet soda, etc.) during the fasting hours and required to record daily food consumption in the smartphone app for 6 months. Participants are also coached by telephone over approximately 10-15 minutes weekly for 1 month and then biweekly for 5 months.
Intervention Type
Behavioral
Intervention Name(s)
behavioral dietary intervention
Intervention Description
Follow tRD
Intervention Type
Behavioral
Intervention Name(s)
telephone-based intervention
Intervention Description
Receive coaching calls
Intervention Type
Other
Intervention Name(s)
laboratory biomarker analysis
Intervention Description
Correlative studies
Primary Outcome Measure Information:
Title
Adherence to self-monitoring
Description
Assessed by demonstrating that at least 65% of participants record dietary intake on at least 80% of study intervention days. Adherence will be assessed via a one-sample chi-squared test for proportions.
Time Frame
Up to 3 months after completion of study
Title
Attaining the goal of dietary time restriction
Description
Assessed by demonstrating that at least 65% of participants recorded appropriate time restriction on at least 80% of study days.
Time Frame
Up to 3 months after completion of study
Secondary Outcome Measure Information:
Title
Changes in steroid hormones (estradiol, progesterone, testosterone) levels
Description
Blood samples will be taken and representative values (mean, standard deviation, median, and range) of hormones and adipokine measurements will be used to calculate changes following intervention, which will then be used for univariate analysis using menopausal status and change in BMI as the main predictors of interest. These analyses are exploratory and descriptive of the systemic endocrine/adipokine environment; they will be related to gene expression changes. Correlations between changes in BMI and changes in biomarker levels will be assessed via the Spearman correlation.
Time Frame
Baseline to up to 3 months after completion of study
Title
Changes in gonadotropins (FSH) levels
Description
Blood samples will be taken and representative values (mean, standard deviation, median, and range) of hormones and adipokine measurements will be used to calculate changes following intervention, which will then be used for univariate analysis using menopausal status and change in BMI as the main predictors of interest. These analyses are exploratory and descriptive of the systemic endocrine/adipokine environment; they will be related to gene expression changes. Correlations between changes in BMI and changes in biomarker levels will be assessed via the Spearman correlation.
Time Frame
Baseline to up to 3 months after completion of study
Title
Changes in insulin axis (insulin, insulin-like growth factor 1, IGF binding protein 3, homeostatic model assessment, homocystein) levels
Description
Blood samples will be taken and representative values (mean, standard deviation, median, and range) of hormones and adipokine measurements will be used to calculate changes following intervention, which will then be used for univariate analysis using menopausal status and change in BMI as the main predictors of interest. These analyses are exploratory and descriptive of the systemic endocrine/adipokine environment; they will be related to gene expression changes. Correlations between changes in BMI and changes in biomarker levels will be assessed via the Spearman correlation.
Time Frame
Baseline to up to 3 months after completion of study
Title
Changes in adipokines (leptin, adiponectin, low molecular weight adiponectin) levels
Description
Blood samples will be taken and representative values (mean, standard deviation, median, and range) of hormones and adipokine measurements will be used to calculate changes following intervention, which will then be used for univariate analysis using menopausal status and change in BMI as the main predictors of interest. These analyses are exploratory and descriptive of the systemic endocrine/adipokine environment; they will be related to gene expression changes. Correlations between changes in BMI and changes in biomarker levels will be assessed via the Spearman correlation.
Time Frame
Baseline to up to 3 months after completion of study
Title
Changes in inflammatory axis (interleukin-6, tumor necrosis factor alpha) levels
Description
Blood samples will be taken and representative values (mean, standard deviation, median, and range) of hormones and adipokine measurements will be used to calculate changes following intervention, which will then be used for univariate analysis using menopausal status and change in BMI as the main predictors of interest. These analyses are exploratory and descriptive of the systemic endocrine/adipokine environment; they will be related to gene expression changes. Correlations between changes in BMI and changes in biomarker levels will be assessed via the Spearman correlation.
Time Frame
Baseline to up to 3 months after completion of study
Title
Changes in weight
Description
The pre- and post-intervention measures and within-individual changes in weight be summarized and examined for Normality and outliers; required transformations to achieve Normality will be performed.
Time Frame
Baseline to up to 3 months after completion of study
Title
Changes in BMI
Description
The pre- and post-intervention measures and within-individual changes in BMI will be summarized and examined for Normality and outliers; required transformations to achieve Normality will be performed. Pre-post comparisons of BMI will be performed using paired Wilcoxon signed-rank tests to evaluate changes over time, designating P < 0.05 as significant.
Time Frame
Baseline to up to 3 months after completion of study
Title
Changes in breast epithelial gene expression
Description
Gene expression for all 58 genes on the Taqman low density gene expression assays will be summarized to confirm normality and discern outliers. Each gene will then be analyzed using a linear model with the main effect of menopausal status and change in BMI, baseline gene expression and change in expression will be correlated to baseline steroid hormones and adipokines, and their change. If severe departure from normality is observed, these linear models will be applied to ranks of the data.
Time Frame
Baseline to up to 3 months after completion of study
Title
Changes in parenchymal volume assessed by MRI
Description
The volume of parenchymal enhancement on MRI will be assessed pre and post intervention in women who consent to this optional component.
Time Frame
Baseline to up to 3 months after completion of study

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Subjects must have a stable weight (have not gained or lost 25 pounds in the last 6 months) Subjects must have had a normal mammogram within 9 months prior to registration; NOTE: subjects must also have a normal breast exam on the day of the pre-intervention random fine needle aspiration (rFNA) Subjects must have a body mass index (BMI) of 25-40 Subjects must fit into ONE of the following menopausal categories: Premenopausal (n = 40) - defined as meeting all the following criteria: Have had at least 8 menstrual cycles in the past 12 months Have had no hormonal contraception in the past 3 months prior to registration Have serum hormone parameters (estradiol [E2], progesterone, follicle stimulating hormone [FSH]) in premenopausal range on the day of rFNA; NOTE: subjects will self-report menopausal status at registration, and confirmation of hormonal parameters will occur after registration as part of pre-intervention procedures; if there is mis-assignment of status, the recruitment of future subjects will be adjusted accordingly Postmenopausal (n = 40) - defined as meeting all of the following criteria: Last menstrual period (LMP) > 1 year previously Have had no hormone use in the past 3 months prior to registration Serum E2, progesterone, FSH in postmenopausal range on the day of rFNA; NOTE: subjects will self-report menopausal status at registration, and confirmation of hormonal parameters will occur after registration as part of pre-intervention procedures; if there is mis-assignment of status, the recruitment of future subjects will be adjusted accordingly Subjects must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 Subjects who have been diagnosed with a prior cancer at any site (other than breast cancer) may participate as long as they have been off medical therapy for at least 12 months prior to registration Subjects with prior breast cancer must be off all systemic therapy (including endocrine agents) for at least 2 years prior to registration Subjects must be willing to undergo a random fine needle aspiration (rFNA) at the beginning and end of the intervention period Subjects must be willing and able to abstain from the use of aspirin for at least 2 weeks prior to undergoing each rFNA procedure (pre- and post-intervention) Subjects must have the ability to understand and the willingness to sign a written informed consent prior to registration on study Subjects must have a smart phone (newer generation Android or any Iphone) to be able to track their food intake times Subjects must be willing to restrict food intake to an 8 hour period every day (12 pm to 8 pm) Exclusion Criteria: Subjects who have received hormonal contraception and/or hormone therapy in the past 3 months are not eligible Subjects who are pregnant and/or lactating are not eligible Subjects who are noted (upon initial online screening) to do 150 minutes or more of moderate level physical activity each week, get less than 8% of their calories from saturated fat, and eat more than 5 fruit and vegetable servings per day will not be eligible Subjects who are part of any structured weight loss programs (e.g. Weight Watchers, etc.) are not eligible Subjects who have undergone bariatric surgery are not eligible Subjects who work night shifts are not eligible Subjects who have diabetes or uncontrolled hypertension are not eligible; NOTE: for the purposes of this study, uncontrolled will be defined as diastolic pressure over 100 mmHg
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Seema Khan
Organizational Affiliation
Northwestern University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Northwestern University
City
Chicago
State/Province
Illinois
ZIP/Postal Code
60611
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Time Restricted Diet in Obese or Overweight Pre or Postmenopausal Participants

We'll reach out to this number within 24 hrs